Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026

12 new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its September 2026 meeting.The committee recommended…, CHMP statistics Key figures from the September 2026 CHMP meeting are represented in the graphic below. © European Medicines Agency, CHMP statistics:…, Positive recommendations on new medicines, Frehemgo International non-proprietary name (INN) denecimig Marketing authorisation applicant Novo Nordisk A/S Therapeutic indication Treatment of prophylaxis…, Gevalka INN ensartinib Marketing authorisation applicant SFL Pharmaceuticals Deutschland GmbH Therapeutic indication The treatment of adult patients with…, Klygefa INN gefurulimab Marketing authorisation applicant Alexion Europe Therapeutic indication Treatment of adult patients with generalised myasthenia gravis…, Lifyorli INN relacorilant Marketing authorisation applicant Corcept Therapeutics Netherlands B.V Therapeutic indication Lifyorli in combination with nab-…, Povofortay INN povorcitinib Marketing authorisation applicant Incyte Biosciences Distribution B.V Therapeutic indication Treatment of active moderate to…, Sepalna INN senaparib  ...